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About a third of affected individuals present with polyps by age 10, and by age 20, about half have clinical signs and symptoms. 2  Affected people also typically have mucocutaneous pigmented lesions -lip freckling is classic, but pigmentation may also develop in the mouth, gums, nose, perianal area, and on the fingers and toes. 1, 2  In addition to gastrointestinal polyps and cancer, people with PJS have an increased risk for other cancers, including those of the pancreas, lung, breast, uterus, cervix, ovaries, and testes. o Ninety-four to 96% of individuals with PJS will have an STK11 pathogenic variant. 5, 6 The detection rate in familial versus sporadic cases is 87% and 97.8%, respectively. 6  STK11 Known Familial Mutation Analysis: Once an STK11 mutation is identified in an affected person, predictive testing is available for at-risk family members, as is prenatal or preimplantation genetic diagnosis 1 Family members should be tested using the method that can accurately identify the familial mutation.
 A multi-gene panel can also be used to test individuals suspected of having PJS.
Guidelines and evidence
 Evidence-based guidelines for the diagnosis and management of PJS were published in 2010. 2 These guidelines outline clinical diagnostic criteria for PJS and surveillance recommendations, but do not specifically address the utility of genetic testing. o Screening procedures and intervals are outlined for breast, colon, stomach, pancreatic, small intestine, cervical, ovarian, uterine, and testicular cancers.
 Clinical diagnostic criteria have been validated by genetic testing in one series of 71 patients.
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Of 56 patients who met clinical criteria for PJS, 94% had an STK11 mutation found by a combination of sequencing and deletion/duplication analysis. Twelve patients had only a "presumptive diagnosis" of PJS based on the presence of hyperpigmentation or isolated PJS polyps, with no known family history. No STK11 mutations were found in those 12 patients.
 A 2016 expert-authored review states:
1 o "Testing of at-risk asymptomatic adults for Peutz-Jeghers syndrome is available after the disease-causing STK11 mutation has been identified in an affected family member."
o "Testing for the disease-causing mutation in the absence of definite symptoms of the disease is predictive testing. At-risk asymptomatic adult family members may seek molecular genetic testing in order to make personal decisions regarding medical surveillance, reproduction, financial matters, and career planning."
o "Because early detection of at-risk individuals who have an STK11 mutation affects medical management, particularly surveillance, testing of at-risk individuals during childhood is beneficial." o "Indications for Genetic Testing: ASCO recommends that genetic testing be offered when 1) the individual has personal or family history features suggestive of a genetic cancer susceptibility condition, 2) the test can be adequately interpreted, and 3) the results will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer."
o "Special Issues in Testing Children for Cancer Susceptibility: ASCO recommends that the decision to offer testing to potentially affected children should take into account the availability of evidence-based risk-reduction strategies and the probability of developing a malignancy during childhood.
Where risk-reduction strategies are available or cancer predominantly develops in childhood, ASCO believes that the scope of parental authority encompasses the right to decide for or against testing." 
Benefit exclusion Exclusions and other considerations
Testing unaffected individuals (e.g. carrier testing, predictive testing, presymptomatic testing, etc) is a BCBSAZ benefit exclusion and, therefore, not eligible for reimbursement.
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